Upon successful completion of the activities, learners should be better able to:
  • RECOGNIZE factors that increase the risk of complications from influenza
  • SELECT effective antiviral treatment strategies for high-risk patients
  • COMPARE the safety and efficacy data of available antiviral therapies for prophylaxis, prevention, and treatment of influenza
  • RECOMMEND age-appropriate vaccines to reduce the risk of complications and spread of influenza infection

Details About the Webinar

Thu, Sep 24, 2020 · 9:00 AM Pacific Time (US & Canada) (GMT -7:00)
Cost: Free
Add to calendar

WEBINAR ENDED
This educational activity is jointly provided by the American College of Emergency Physicians and Spire Learning.

This activity is supported by an educational grant from Genentech, a member of the Roche group.

The American College of Emergency Physicians designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Approved by the American College of Emergency Physicians for 1.0 hour of ACEP Category I credit.
There is no fee to participate in this activity.

About the Speaker

1600270812-5cf76bdef121a78c David A. Talan, MD, FACEP, FIDSA

Faculty and Chairman Emeritus, Department of Emergency Medicine and Department of Medicine, Division of Infectious Diseases
Ronald Reagan UCLA Medical Center
Professor of Medicine in Residence (Emeritus)
David Geffen School of Medicine at UCLA
Los Angeles, CA